Jun 2026 (Q2 FY26) — Aug 5, 2026
Evolus Q2 FY26 — Strong Growth, Raised Outlook, and Strategic Portfolio Expansion
Read the full callEvolus (EOLS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Evolus earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 84.1 | +21.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -5.4 | +9.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -8.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.36 +3.66% · +$0.26
Performance +15.0% 1Y
1Y: $6.4 on 17 Oct 2025 → $7.36. High $9.3 (4 Sept 2026), low $3.94 (30 Mar 2026).
- Previous close
- $7.1
- 52-week range
- $3.94 – $9.3
- One year
- +10.01%
Overview
- Symbol
- EOLS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Evolus earnings calls (EOLS)
Financials
What the filings say
Net profit, year on year: +53% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 61 | 79 | 69 | 69 | 69 | 90 | 73 | 84 |
| Expenses | 58 | -3 | 62 | 56 | 57 | 55 | 56 | 62 |
| Operating profit | -15 | -2 | -15 | -10 | -11 | 4 | -7 | -5 |
| Operating margin | −25.3% | −2.9% | −22.1% | −14.7% | −16.7% | 4.7% | −9.4% | −5.4% |
| Interest | 5 | 5 | 4 | 7 | 4 | 4 | 4 | 4 |
| Profit before tax | -19 | -6 | -19 | -17 | -16 | 1 | -10 | -8 |
| Tax rate | −0.7% | −6.9% | −0.4% | −0.3% | −1.1% | 74.8% | −2.5% | 1.9% |
| Net profit | -19 | -7 | -19 | -17 | -16 | 0 | -11 | -8 |
| EPS ($ per share) | -0.30 | — | -0.30 | -0.27 | -0.24 | — | -0.16 | -0.12 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -123 | -213 | -376 | -423 | -497 | -559 | -609 | -661 |
| Total liabilities | 87 | 161 | 282 | 176 | 159 | 210 | 227 | 249 |
| Fixed assets | 0 | 1 | 1 | 1 | 3 | 2 | 3 | 5 |
| Total assets | 172 | 240 | 209 | 257 | 178 | 189 | 233 | 226 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -26 | -93 | -58 | -33 | -85 | -34 | -18 | -42 |
| Cash from investing | -0 | -23 | 12 | 4 | -3 | -2 | -5 | -8 |
| Cash from financing | 119 | 134 | 38 | 73 | -4 | 45 | 47 | 17 |
| Net cash flow | 93 | — | -7 | 44 | -92 | 9 | 24 | -33 |
| Capital expenditure | -0 | -0 | -1 | -0 | -2 | -0 | -1 | -3 |
| Free cash flow | -26 | -94 | -59 | -34 | -87 | -34 | -19 | -46 |
Insider filings
17 filings between Dec 22, 2025 and Sep 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.84M
7 sales by 2 insiders
71% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 8
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| MOATAZEDI DAVID | — | $1.66M | Sep 2, 2026 |
| Avelar Rui | — | $177.6K | Mar 20, 2026 |
Latest filings (47)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | MOATAZEDI DAVID See Remarks | Sale | 105,108 | $950.0K |
| Mar 20, 2026 | Avelar Rui See Remarks | Sale | 3,119 | $14.8K |
| Mar 20, 2026 | MOATAZEDI DAVID See Remarks | Sale 10b5-1 plan | 13,669 | $64.9K |
| Mar 17, 2026 | MOATAZEDI DAVID See Remarks | Sale 10b5-1 plan | 116,720 | $570.6K |
| Mar 17, 2026 | Avelar Rui See Remarks | Sale 10b5-1 plan | 29,996 | $146.6K |
| Mar 16, 2026 | Avelar Rui See Remarks | Option exercise 10b5-1 plan | 8,804 | $0 |
| Mar 16, 2026 | MOATAZEDI DAVID See Remarks | Option exercise 10b5-1 plan | 67,489 | $0 |
| Feb 17, 2026 | Avelar Rui See Remarks | Award | 94,913 | $0 |
| Feb 17, 2026 | Malik Vikram Director | Award | 45,559 | $0 |
| Feb 17, 2026 | MOATAZEDI DAVID See Remarks | Award | 313,212 | $0 |
| Feb 17, 2026 | White Albert G III Director | Award | 45,559 | $0 |
| Feb 17, 2026 | Mitchell Tatjana Chief Financial Officer | Award | 121,489 | $0 |
| Feb 17, 2026 | Stewart Brady Director | Award | 45,559 | $0 |
| Feb 17, 2026 | Parschauer Karah Herdman Director | Award | 45,559 | $0 |
| Feb 17, 2026 | GILL DAVID N Director | Award | 45,559 | $0 |
| Dec 22, 2025 | MOATAZEDI DAVID See Remarks | Sale 10b5-1 plan | 10,539 | $75.4K |
| Dec 22, 2025 | Avelar Rui See Remarks | Sale 10b5-1 plan | 2,261 | $16.2K |
| Sep 8, 2025 | Mitchell Tatjana Chief Financial Officer | Award | 104,603 | $0 |
| Aug 22, 2025 | Yamagishi-Dressler Tomoko Chief Marketing Officer | Sale 10b5-1 plan | 5,722 | $43.0K |
| Aug 15, 2025 | Stewart Brady Director | Purchase | 30,000 | $204.5K |
| Jun 16, 2025 | MOATAZEDI DAVID See Remarks | Sale | 16,582 | $164.1K |
| Jun 13, 2025 | MOATAZEDI DAVID See Remarks | Sale | 111,323 | $1.12M |
| Jun 9, 2025 | White Albert G III Director | Purchase | 20,000 | $189.0K |
| May 13, 2025 | Beaver Sandra Chief Financial Officer | Sale 10b5-1 plan | 6,494 | $65.1K |
| May 12, 2025 | Avelar Rui See Remarks | Sale 10b5-1 plan | 3,385 | $33.4K |
| May 12, 2025 | MOATAZEDI DAVID See Remarks | Sale 10b5-1 plan | 15,787 | $155.8K |
| Mar 27, 2025 | MOATAZEDI DAVID See Remarks | Sale 10b5-1 plan | 6,251 | $77.5K |
| Mar 18, 2025 | Yamagishi-Dressler Tomoko Chief Marketing Officer | Sale 10b5-1 plan | 4,536 | $60.1K |
| Mar 18, 2025 | Beaver Sandra Chief Financial Officer | Sale 10b5-1 plan | 8,996 | $119.2K |
| Mar 18, 2025 | Avelar Rui See Remarks | Sale 10b5-1 plan | 27,904 | $369.9K |
| Mar 18, 2025 | MOATAZEDI DAVID See Remarks | Sale 10b5-1 plan | 103,376 | $1.37M |
| Mar 12, 2025 | Parschauer Karah Herdman Director | Sale | 12,888 | $167.5K |
| Mar 7, 2025 | Malik Vikram Director | Award | 7,364 | $0 |
| Mar 7, 2025 | White Albert G III Director | Award | 7,364 | $0 |
| Mar 7, 2025 | Stewart Brady Director | Award | 7,364 | $0 |
| Mar 7, 2025 | GILL DAVID N Director | Award | 7,364 | $0 |
| Mar 7, 2025 | BLANK SIMONE Director | Award | 7,364 | $0 |
| Mar 7, 2025 | Avelar Rui See Remarks | Award | 23,776 | $0 |
| Mar 7, 2025 | MOATAZEDI DAVID See Remarks | Award | 95,399 | $0 |
| Mar 7, 2025 | Parschauer Karah Herdman Director | Award | 7,364 | $0 |
| Mar 7, 2025 | Yamagishi-Dressler Tomoko Chief Marketing Officer | Award | 17,832 | $0 |
| Mar 7, 2025 | Beaver Sandra Chief Financial Officer | Award | 35,663 | $0 |
| Dec 23, 2024 | Avelar Rui See Remarks | Sale 10b5-1 plan | 2,252 | $24.4K |
| Dec 23, 2024 | MOATAZEDI DAVID See Remarks | Sale 10b5-1 plan | 10,502 | $114.0K |
| Dec 23, 2024 | Beaver Sandra Chief Financial Officer | Sale 10b5-1 plan | 1,586 | $17.2K |
| Sep 6, 2024 | Beaver Sandra Chief Financial Officer | Sale | 3,276 | $49.1K |
| Aug 30, 2024 | Yamagishi-Dressler Tomoko Chief Marketing Officer | Sale | 5,631 | $89.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Evolus, Inc.
Free account. Everything above stays public.
Write why you follow Evolus, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading